News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Navidea Biopharmaceuticals (NEOP) Announces the Presentation of Data at Upcoming Scientific Meetings in July



7/6/2012 9:37:14 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek program were accepted for presentation at the European Association for Cancer Research (EACR) and the American Head and Neck Society’s 8th International Conference on Head and Neck Cancer Conference. In addition, data from its AZD4694 program were accepted for presentation at the Alzheimer's Association International Conference on Alzheimer's Disease (AAIC). Details of the presentations from the Phase 3 clinical studies investigating Lymphoseek® (Kit for the Preparation of Technetium Tc 99m Tilmanocept for Injection) in head and neck cancer, breast cancer, and melanoma and from Phase 1/Phase 2 clinical trials of its Alzheimer’s Disease candidate, AZD4694 are listed below.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES